Shopping Cart

Your shopping cart is currently empty

Vipivotide tetraxetan

Name: Vipivotide tetraxetan
Brand: TargetMol
SKU: T12573
Price: 193 USD
Availability: InStock
Rating: 5 (10 reviews)

😃Good

Catalog No. T12573Cas No. 1702967-37-0

Alias PSMA-617

Vipivotide tetraxetan (PSMA-617) is a highly potent inhibitor of prostate-specific membrane antigen (PSMA) with a Ki of 0.37 nM.

Vipivotide tetraxetan

😃Good

Purity: 99.9%

Catalog No. T12573Alias PSMA-617Cas No. 1702967-37-0

Vipivotide tetraxetan (PSMA-617) is a highly potent inhibitor of prostate-specific membrane antigen (PSMA) with a Ki of 0.37 nM.

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$193	In Stock	In Stock
2 mg	$287	In Stock	In Stock
5 mg	$483	In Stock	In Stock
10 mg	$691	In Stock	In Stock
25 mg	$1,080	In Stock	In Stock
50 mg	$1,490	In Stock	In Stock
100 mg	$1,960	-	In Stock
1 mL x 10 mM (in DMSO)	$1,190	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.9%

Appearance:Solid

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	Vipivotide tetraxetan (PSMA-617) is a highly potent inhibitor of prostate-specific membrane antigen (PSMA) with a Ki of 0.37 nM.
Targets&IC50	LNCaP cells:2.34 - 2.94 nM (Ki), PSMA:0.37 nM (Ki)
In vitro	The chemically modified PSMA inhibitor PSMA-617 demonstrated high radiolytic stability for at least 72 h. A high inhibition potency (equilibrium dissociation constant [K(i)] = 2.34 2.94 nM on LNCaP; K(i) = 0.37 0.21 nM enzymatically determined) and highly efficient internalization into LNCaP cells were demonstrated.
In vivo	The small-animal PET measurements showed high tumor-to-background contrasts as early as 1 h after injection of Vipivotide tetraxetan.Organ distribution revealed specific uptake in LNCaP tumors and in the kidneys 1 h after injection of Vipivotide tetraxetan[1].
Synonyms	PSMA-617

Chemical Properties

Molecular Weight	1042.14
Formula	C₄₉H₇₁N₉O₁₆
Cas No.	1702967-37-0
Smiles	OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@H]1CC[C@H](CNC(=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)CC1)C(O)=O)C(O)=O
Relative Density.	1.322 g/cm3 (Predicted)

Storage & Solubility Information

Storage

store at low temperature | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 100 mg/mL (95.96 mM), Sonication is recommended.

H2O: 100 mg/mL (95.96 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (3.84 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO/H2O

	1mg	5mg	10mg	50mg
1 mM	0.9596 mL	4.7978 mL	9.5956 mL	47.9782 mL
5 mM	0.1919 mL	0.9596 mL	1.9191 mL	9.5956 mL
10 mM	0.0960 mL	0.4798 mL	0.9596 mL	4.7978 mL
20 mM	0.0480 mL	0.2399 mL	0.4798 mL	2.3989 mL
50 mM	0.0192 mL	0.0960 mL	0.1919 mL	0.9596 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc